Abstracts

Investigation of the Functional Role of DDX42 in HIV-1 Viral RNA Splicing

Background: Understanding the mechanism of HIV-1 viral RNA splicing could lead to the discovery of therapeutic potential drugs that target HIV-1 viral splicing pathways. HIV-1 splicing is regulated by cis-acting regulatory sequences and trans-acting splicing factors. We aim to identify host splicing factors that play roles in HIV-1 splicing through high-throughput assays. Methods: We generated…

Structural Basis of Translation Inhibition by MERS-CoV Nsp1 Reveals a Conserved Mechanism for β-CoVs

Background: Since 2002, three deadly human betacoronaviruses (β-CoVs) have emerged: SARS-CoV, MERS, and SARS-CoV-2, however our therapeutic arsenal remains inadequate to restrict current and novel β-CoVs. All β-CoVs encode non-structural protein 1 (Nsp1), an essential pathogenicity factor that potently inhibits host gene expression. Three distinct mechanisms are proposed for Nsp1: two cytosolic involving the ribosome…

HIV-1 Transcription Start Sites Usage and Its Impact on Unspliced RNA Functions In Vivo

Background: HIV-1 unspliced RNA plays two crucial roles in viral replication: it is packaged into particles to serve as viral genome, and it is translated to generate Gag/Gag-Pol polyproteins required for virus assembly and replication. Studies using cell culture systems demonstrated that HIV-1 transcription can initiate at three conserved consecutive guanosines located at the junction…

Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083

Background: Bacterial sexually transmitted infections (STIs) have been shown to facilitate HIV transmission and acquisition. Long-acting cabotegravir (CAB-LA) demonstrated superiority vs daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention in two large randomized controlled trials, but an assessment of efficacy in the setting of STIs has not been performed. Methods: From the blinded period…

Molnupiravir Does Not Increase 3CLpro Resistance Mutations When Co-Administered With Nirmatrelvir/r

Background: Current treatments for SARS-CoV-2 rely on direct-acting antivirals including the 3CLpro inhibitor nirmatrelvir/r (NMV/r) and the mutagenic nucleoside analog molnupiravir (MOV). There have been concerns regarding the use of MOV including the generation of new viral variants. In a previous study, we compared the antiviral effect of MOV or NMV/r alone, or the co-administration…

Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies

Background: Human immunodeficiency virus type 1 (HIV-1) specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown limited therapeutic efficacy when administered as monotherapy or as a cocktail of two antibodies. A combination of three bNAbs provides improved neutralization coverage of global viruses. Here we show that a triple bNAb cocktail targeting three distinct epitopes…

Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women

Background: Long-acting antiretroviral formulations offer an innovative solution to support adherence in African women seeking HIV pre-exposure prophylaxis. Micro-tabletted tenofovir alafenamide (TAF), a potent antiretroviral drug with established systemic safety, was formulated in a silicone elastomer sub-dermal implant and tested for safety, tolerability, and pharmacokinetics (PK). Methods: Healthy, adult South African women at low HIV…